Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

House subpanel approves a boost for device center

This article was originally published in The Gray Sheet

Executive Summary

A House Appropriations subcommittee approved on June 30 a $7 million increase over the $325.7 million that the Obama administration had requested for CDRH's fiscal year 2011 budget ("1The Gray Sheet" Feb. 8, 2010). The subcommittee version of the bill would provide FDA with a total of $3.77 billion for the fiscal year beginning Oct. 1, including $2.57 billion in federal funds and $1.2 billion from various industry user fees. The funds include a $65 million package aimed at bolstering staff reviews of generic drug applications and drug company ads, as well as "more funds to safeguard clinical trials," Subcommittee Chair Rosa DeLauro, D-Conn., said. The bill now goes to the House Appropriations Committee for refinements and approval. The Senate Appropriations subcommittee with jurisdiction has yet to propose funding levels for FDA
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

MT029087

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel